Spinal Muscular Atrophy (SMA) Clinical Trial
Official title:
An Open-Label, Non-Comparative Clinical Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene (ANB-004 (JSC BIOCAD, Russia)) After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy
The goal of this multicenter, open-label, non-comparative, cohort study is to investigate the safety, immunogenicity, and efficacy of ANB-004 in children with spinal muscular atrophy. The study will have a standard 3+3 dose-escalation design.
The study will be conducted in 2 stages: Stage 1: pilot efficacy and safety study of different doses to select a potentially therapeutic dose for further study. Stage 2: study of the efficacy and safety of ANB-004 at the selected potentially therapeutic dose. At the first stage, the study will have a "3+3" design and involve dose escalation in two cohorts, with the possibility of including a third cohort. Three subjects are to be included in each cohort, each of whom will receive a pre-specified cohort dose of ANB-004 as a single intravenous infusion. Subjects will be monitored for dose-limiting toxicity (DLT) events for 3 weeks after the drug infusion. In this study, DLT will include any of the CTCAE 5.0 grade 3 or higher adverse events (AEs) at least possibly related to the administration of the investigational product, except for an increase in body temperature at least possibly related to the administration of the investigational product, which will be classified as DLT starting from CTCAE 5.0 grade 4. At the first stage, in the absence of DLT events in three subjects in the same cohort, an ID will be assigned, and an infusion will be administered to the first subject in subsequent cohort. If DLT events occur in 1 of 3 subjects in the same cohort, this cohort will additionally include 3 subjects who will receive the same ANB-004 dose with which the DLT event was observed. If DLT events occur in 2 or more of 3 subjects within the same cohort, the assignment of ID/infusion in subsequent subjects/study is suspended. AT the second stage, if the IDMC judges that the potentially therapeutic dose was previously used in one of the cohorts, an additional 6 subjects will be included in this cohort. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04174157 -
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
|
||
| Recruiting |
NCT05354414 -
Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy
|
N/A | |
| Recruiting |
NCT05115110 -
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
|
Phase 2/Phase 3 | |
| Terminated |
NCT02876094 -
Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy
|
Phase 2 | |
| Completed |
NCT01736553 -
Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development
|
||
| Recruiting |
NCT05335876 -
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
|
Phase 3 | |
| Withdrawn |
NCT01663584 -
Multi-disease Carrier Screening Test Validation
|
N/A |